MiR-125a promotes paclitaxel sensitivity in cervical cancer through altering STAT3 expression

Oncogenesis

Volumn 5, Issue , 2016, Pages

  Fan, Z ^a   Cui, H ^b   Yu, H ^a   Ji, Q ^a   Kang, L ^c   Han, B ^d   Wang, J ^a   Dong, Q ^a   Li, Y ^a   Yan, Z ^a   Yan, X ^a   Zhang, X ^a   Lin, Z ^a   Hu, Y ^a   Jiao, S ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b 309TH HOSPITAL OF PLA   (China)

^c PEKING UNIVERSITY FIRST HOSPITAL   (China)

^d 264th Hospital of PLA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MICRORNA; MICRORNA 125A; PACLITAXEL; PROTEIN BCL 2; PROTEIN BCL XL; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; UPREGULATION; UTERINE CERVIX CANCER;

EID: 84958254330     PISSN: None     EISSN: 21579024     Source Type: Journal    
DOI: 10.1038/oncsis.2016.1     Document Type: Article

References (39)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
4. Moore KN, Herzog TJ, Lewin S, Giuntoli RL, Armstrong DK, Rocconi RP et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 2007; 105: 299-303.
5. Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 2015; 33: 2129-2135.
6. Kudelka AP, Winn R, Edwards CL, Downey G, Greenberg H, Dakhil SR et al. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 1997; 8: 657-661.
7. Zheng H, Liu Z, Liu T, Cai Y, Wang Y, Lin S et al. Fas signaling promotes chemoresistance in gastrointestinal cancer by up-regulating P-glycoprotein. Oncotarget 2014; 5: 10763-10777.
8. Vargas JR, Stanzl EG, Teng NN, Wender PA. Cell-penetrating, guanidinium-rich molecular transporters for overcoming efflux-mediated multidrug resistance. Mol Pharm 2014; 11: 2553-2565.
9. Goncalves A, Braguer D, Kamath K, Martello L, Briand C, Horwitz S et al. Resistance to Taxol in lung cancer cells associated with increased microtubule dynamics. Proc Natl Acad Sci USA 2001; 98: 11737-11742.
10. He W, Zhang D, Jiang J, Liu P, Wu C. The relationships between the chemosensitivity of human gastric cancer to paclitaxel and the expressions of class III ?-tubulin, MAPT, and survivin. Med Oncol 2014; 31: 950.
11. Kavallaris M. Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 2010; 10: 194-204.
12. Ingemarsdotter CK, Tookman LA, Browne A, Pirlo K, Cutts R, Chelela C et al. Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control. Mol Oncol 2015; 9: 791-805.
13. Choi JH, Sheu JJ, Guan B, Jinawath N, Markowski P, Wang TL et al. Functional analysis of 11q13.5 amplicon identifies Rsf-1 (HBXAP) as a gene involved in paclitaxelresistance in ovarian cancer. Cancer Res 2009; 69: 1407-1415.
14. Le XF, Bast RC Jr. Src family kinases and paclitaxel sensitivity. Cancer Biol Ther 2011; 12: 260-269.
15. Peng X, Gong F, Chen Y, Jiang Y, Liu J, Yu M et al. Autophagy promotes paclitaxel resistance of cervical cancer cells: involvement of Warburg effect activated hypoxia-induced factor 1-?-mediated signaling. Cell Death Dis 2014; 5: e1367.
16. Chatterjee A, Chattopadhyay D, Chakrabarti G. MiR-16 targets Bcl-2 in paclitaxelresistant lung cancer cells and overexpression of miR-16 along with miR-17 causes unprecedented sensitivity by simultaneously modulating autophagy and apoptosis. Cell Signal 2015; 27: 189-203.
17. Chatterjee A, Chattopadhyay D, Chakrabarti G. miR-17-5p downregulation contributes to paclitaxel resistance of lung cancer cells through altering beclin1 expression. PLoS ONE 2014; 9: e95716.
18. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006; 34: (Database issue) D140-D144.
19. Kanakkanthara A, Miller JH. MicroRNAs: novel mediators of resistance to microtubule-targeting agents. Cancer Treat Rev 2013; 39: 161-170.
20. Sun YM, Lin KY, Chen YQ. Diverse functions of miR-125 family in different cell contexts. J Hematol Oncol 2013; 6: 6.
21. Chen J, Chen Y, Chen Z. MiR-125a/b regulates the activation of cancer stem cells in paclitaxel-resistant colon cancer. Cancer Invest 2013; 31: 17-23.
22. Chen JJ, Liu SX, Chen MZ, Zhao ZY. Has-miR-125a and 125b are induced by treatment with cisplatin in nasopharyngeal carcinoma and inhibit apoptosis in a p53-dependent manner by targeting p53 mRNA. Mol Med Rep 2015; 12: 3569-3574.
23. Pan W, Zhu S, Dai D, Liu Z, Li D, Li B et al. MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis. Nat Commun 2015; 6: 7096.
24. Wang C, Li D, Zhang S, Xing Y, Gao Y, Wu J. MicroRNA-125a-5p induces mouse granulosa cell apoptosis by targeting signal transducer and activator of transcription 3. Menopause 2015; 23: 100-107.
25. Lee JH, Kim C, Sethi G, Ahn KS. Brassinin inhibits STAT3 signaling pathway through modulation of PIAS-3 and SOCS-3 expression and sensitizes human lung cancer xenograft in nude mice to paclitaxel. Oncotarget 2015; 6: 6386-6405.
26. Al-Dimassi S, Abou-Antoun T, El-Sibai M. Cancer cell resistance mechanisms: a mini review. Clin Transl Oncol 2014; 16: 511-516.
27. Periti P, Mini E. Drug resistance in cancer: an overview of the clinical aspects. J Chemother 1989; 1: 5-9.
28. Shen Y, Wang P, Li Y, Ye F, Wang F, Wan X et al. miR-375 is upregulated in acquired paclitaxel resistance in cervical cancer. Br J Cancer 2013; 109: 92-99.
29. Li B, Ren S, Li X, Wang Y, Garfield D, Zhou S et al. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer. Lung Cancer 2014; 83: 146-153.
30. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007; 282: 1479-1486.
31. Fassan M, Pizzi M, Realdon S, Balistreri M, Guzzardo V, Zagonel V et al. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. Hum Pathol 2013; 44: 1804-1810.
32. Dai J, Wang J, Yang L, Xiao Y, Ruan Q. miR-125a regulates angiogenesis of gastric cancer by targeting vascular endothelial growth factor A. Int J Oncol 2015; 47: 1801-1810.
33. Ninio-Many L, Grossman H, Levi M, Zilber S, Tsarfaty I, Shomron N et al. MicroRNA miR-125a-3p modulates molecular pathway of motility and migration in prostate cancer cells. Oncoscience 2014; 1: 250-261.
34. Dimitrakopoulou K, Vrahatis AG, Bezerianos A. Integromics network meta-analysis on cardiac aging offers robust multi-layer modular signatures and reveals micronome synergism. BMC Genomics 2015; 16: 147.
35. Wong LL, Armugam A, Sepramaniam S, Karolina DS, Lim KY, Lim JY et al. Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 2015; 17: 393-404.
36. Squillace N, Bresciani E, Torsello A, Bandera A, Sabbatini F, Giovannetti C et al. Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients. J Antimicrob Chemother 2014; 69: 3067-3075.
37. Inchley CS, Sonerud T, Fjærli HO, Nakstad B. Nasal mucosal microRNA expression in children with respiratory syncytial virus infection. BMC Infect Dis 2015; 15: 150.
38. Huang WL, Yeh HH, Lin CC, Lai WW, Chang JY, Chang WT et al. Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells. Mol Cancer 2010; 9: 309.
39. Fu J, Xu X, Kang L, Zhou L, Wang S, Lu J et al. miR-30a suppresses breast cancer cell proliferation and migration by targeting Eya2. Biochem Biophys Res Commun 2014; 445: 314-319.